ARAVIVE (ARAV) Competitors $0.04 0.00 (0.00%) As of 08/15/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsSustainabilityTrendsBuy This Stock ARAV vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying ARAVIVE stock or one of its competitors? The main competitors of ARAVIVE include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. ARAVIVE vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity ARAVIVE (NASDAQ:ARAV) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings. Is ARAV or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets ARAVIVEN/A N/A N/A 180 Life Sciences N/A N/A N/A Does the media prefer ARAV or ATNFW? In the previous week, 180 Life Sciences had 4 more articles in the media than ARAVIVE. MarketBeat recorded 4 mentions for 180 Life Sciences and 0 mentions for ARAVIVE. 180 Life Sciences' average media sentiment score of 1.01 beat ARAVIVE's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment ARAVIVE Neutral 180 Life Sciences Positive Do insiders & institutionals have more ownership in ARAV or ATNFW? 35.8% of ARAVIVE shares are held by institutional investors. 60.4% of ARAVIVE shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation & earnings, ARAV or ATNFW? 180 Life Sciences has lower revenue, but higher earnings than ARAVIVE. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARAVIVE$9.14MN/A-$76.32MN/AN/A180 Life SciencesN/AN/AN/AN/AN/A SummaryARAVIVE beats 180 Life Sciences on 3 of the 5 factors compared between the two stocks. Get ARAVIVE News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARAV vs. The Competition Export to ExcelMetricARAVIVEMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E RatioN/A20.7930.8625.27Price / SalesN/A232.09403.8888.61Price / CashN/A41.5625.2228.45Price / BookN/A9.749.516.00Net Income-$76.32M-$54.74M$3.26B$265.34M7 Day PerformanceN/A8.13%4.50%2.79%1 Month PerformanceN/A7.74%5.22%1.51%1 Year PerformanceN/A18.08%31.92%25.40% ARAVIVE Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeATNFW180 Life SciencesN/A$0.01-6.6%N/A+4,958.8%$0.00N/A0.007Positive NewsGap UpLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.45+54.4%N/AN/A$0.00$106.21K0.0040Gap UpALVOWAlvotechN/A$1.33+4.7%N/A-68.5%$0.00$585.60M0.004Positive NewsGap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.06flatN/AN/A$0.00N/A0.0015Gap DownBFRIWBiofronteraN/A$0.14flatN/A+118.7%$0.00$38.00M0.0070Positive NewsBTMDWbioteN/A$0.01+21.0%N/A-97.9%$0.00$199.07M0.00N/AGap DownHigh Trading VolumeBCTXWBriaCell TherapeuticsN/A$0.03-5.1%N/A-87.5%$0.00N/A0.008Positive NewsGap DownCELUWCelularityN/A$0.05+11.6%N/AN/A$0.00$54.22M0.00220News CoveragePositive NewsGap Down Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors CELUW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARAV) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARAVIVE, INC Please log in to your account or sign up in order to add this asset to your watchlist. Share ARAVIVE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access